Skip to main content
Springer logoLink to Springer
. 2019 Nov 26;79(18):2013. doi: 10.1007/s40265-019-01239-1

Correction to: Dapagliflozin: A Review in Type 2 Diabetes

Sohita Dhillon 1,
PMCID: PMC6943399  PMID: 31773635

Correction to: Drugs (2019) 79:1135–1146 10.1007/s40265-019-01148-3

The article Dapagliflozin: A Review in Type 2 Diabetes, written by Sohita Dhillon, was originally published Online First without Open Access. After publication in volume 79, issue 10, pages 1135–1146 AstraZeneca Pharmaceuticals, LP requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AstraZeneca Pharmaceuticals, LP. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.

The original article has been corrected.


Articles from Drugs are provided here courtesy of Springer

RESOURCES